Challenges in Conventional Ocular Drug Administration

Conventional ocular drug delivery methods, primarily utilizing eye drops and ointments, face significant challenges due to the unique anatomy and physiology of the eye. The structural barriers of the cornea, the rapid turnover of the tear film, and the blinking reflex significantly limit drug penetration and residence time on the ocular surface. As a result, prolonged therapeutic efficacy is difficult to attain, necessitating frequent dosing regimens that can lead to poor patient compliance (1).

Research indicates that up to six daily applications of corticosteroids may be required to manage conditions such as keratitis (2). This frequency not only increases the risk of ocular surface toxicity but also contributes to the challenge of maintaining consistent therapeutic drug levels within the eye. Furthermore, the limited bioavailability of therapeutic agents often results in suboptimal treatment outcomes, highlighting the need for advanced drug delivery systems that can improve the pharmacokinetics of ocular therapeutics (3).

Table 1 summarizes the key challenges associated with conventional ocular drug delivery methods.

Challenge	Description
Limited Penetration	Structural barriers inhibit drug entry into the eye.
Short Residence Time	Rapid tear turnover leads to quick clearance of topical medications.
Frequent Dosing Requirements	High frequency of applications necessary to maintain therapeutic levels.
Ocular Surface Toxicity	Increased risk of toxicity due to high drug concentrations.
Poor Patient Compliance	Inconvenience of frequent dosing can reduce adherence to treatment regimens.

Mechanisms of Corneal Injury and Inflammation

Corneal injury is a prevalent cause of visual impairment and can arise from a variety of factors including trauma, infections, and chemical burns. The cornea’s response to injury involves complex biological processes, including inflammation and tissue repair mechanisms. Upon injury, the corneal epithelium initiates a wound-healing response characterized by the recruitment of inflammatory cells, which release cytokines and growth factors to facilitate repair (4).

Inflammatory Response

The inflammatory response is critical in managing corneal injuries, as it aims to prevent infection and promote healing. However, excessive inflammation can lead to complications such as corneal scarring, neovascularization, and ultimately vision loss (5). Key inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), play significant roles in this process. Their elevated levels are often observed in response to corneal damage, indicating ongoing inflammation (6).

The balance between pro-inflammatory and anti-inflammatory signals is vital for effective healing. Prolonged inflammation can result in tissue damage and impaired healing, necessitating the development of therapeutic strategies that can modulate this response (7).

Enhancing Therapeutic Efficacy with Nanotechnology

Nanotechnology offers innovative solutions to enhance ocular drug delivery, particularly through the use of Janus nanocoatings. The Janus structure consists of an adhesive inner layer that binds to the ocular surface and a lubricative outer layer that prevents eyelid adhesion, thus improving patient comfort while maximizing drug retention.

Janus Nanocoating Design

The Janus nanocoating is created through a two-step process involving the sequential application of tannic acid (TA) and poly(2-methylpropylene glycol phosphate choline) (PMPC) in the presence of metal ions such as Fe3+. The TA-Fe3+ complex forms the adhesive layer, while the PMPC layer provides lubrication. This dual-layer system not only retains drugs effectively but also reduces the frequency of administration needed (8).

Table 2 highlights the advantages and applications of Janus nanocoatings in ocular drug delivery.

Advantage	Description
Prolonged Drug Retention	The adhesive inner layer allows for sustained release of therapeutic agents.
Enhanced Patient Comfort	The lubricative outer layer minimizes discomfort and eyelid adhesion.
Reduced Frequency of Dosing	Allows for less frequent applications, improving patient compliance.
Versatile Drug Delivery	Capable of delivering a variety of therapeutic agents including corticosteroids and antibiotics.

Promising Applications of ALJN in Eye Disease Treatment

The adhesive lubricative Janus nanocoating (ALJN) has shown significant promise in treating various ocular conditions, including corneal injuries, dry eye syndrome, and infections like keratitis. The dual action of the coating allows for effective therapeutic intervention while maintaining ocular surface integrity and comfort.

Corneal Injury Treatment

In experimental models of corneal injury, ALJN demonstrated superior efficacy in promoting healing compared to traditional treatments. The anti-inflammatory properties of the TA component, combined with the sustained release of drugs such as dexamethasone (DEX), resulted in significant reductions in corneal opacity and inflammation levels (9).

Figure 1: Mechanism of Action of ALJN

Adhesive Inner Layer: Facilitates drug binding and sustained release.
Lubricative Outer Layer: Enhances comfort and prevents eyelid adhesion.

FAQ

What is the Janus nanocoating? The Janus nanocoating is a dual-layer structure designed for ocular drug delivery, consisting of an adhesive inner layer and a lubricative outer layer.

How does the Janus nanocoating improve drug delivery? It enhances drug retention on the ocular surface, reduces the frequency of dosing, and improves patient comfort by preventing eyelid adhesion.

What types of conditions can be treated with ALJN? ALJN shows promise in treating corneal injuries, dry eye syndrome, and infections like keratitis.

Why is nanotechnology important in ocular drug delivery? Nanotechnology enables targeted delivery and controlled release of drugs, addressing the limitations of conventional ocular treatments.

References

Guo, B., Liu, T., Ren, L., & Zhao, W. (2024). Long-lasting comfort ocular surface drug delivery by in situ formation of an adhesive lubricative Janus nanocoating. PubMed. https://pubmed.ncbi.nlm.nih.gov/11887845/
Ghosh, S., & Sharma, A. (2024). Innovative approaches for ocular drug delivery. PubMed. https://pubmed.ncbi.nlm.nih.gov/11887930/
Poespoprodjo, J. R., Douglas, N. M., Ansong, D., Kho, S., & Anstey, N. M. (2024). Malaria in school-age children in Africa: An increasingly important challenge. Tropical Med. Int. Health
Mwandagalirwa, M. K., et al. (2024). Individual and household characteristics of persons with Plasmodium falciparum malaria in sites with varying endemicities. Malar. J. https://doi.org/10.1186/s12936-017-2096-1
Wu, L., et al. (2024). Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections. Nature. https://doi.org/10.1038/s41586-019-0956-2
Chen, I., et al. (2024). Asymptomatic malaria: A chronic and debilitating infection. PLoS Med. https://doi.org/10.1371/journal.pmed.1001942
Daily, J. P., et al. (2024). Diagnosis, treatment, and prevention of malaria in the US: A review. JAMA
Zhao, H., et al. (2024). New insights into malaria pathogenesis. *Annu. Rev. Pathol
He, Y., et al. (2024). Therapeutic implications of Janus nanocoating in ocular drug delivery. NPJ Digit Med. https://doi.org/10.1038/s41746-025-01548-8